

Defining suicidality phenotypes for genetic studies: perspectives of the Psychiatric Genomics Consortium Suicide Working Group

Item Type	Article (Version of Record)
UoW Affiliated Authors	Jones, Lisa
Full Citation	The Psychiatric Genomics Consortium Suicide Working Group, including, Jones, Lisa and et, al. (2025) Defining suicidality phenotypes for genetic studies: perspectives of the Psychiatric Genomics Consortium Suicide Working Group. <i>Molecular Psychiatry</i> , 30. pp. 6144-6154. ISSN Print: 1359-4184 Online: 1476-5578
DOI/ISBN/ISSN	https://doi.org/10.1038/s41380-025-03271-y
Journal/Publisher	<i>Molecular Psychiatry</i> Nature
Rights/Publisher Set Statement	© The Author(s) 2025, Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, http://creativecommons.org/licenses/by-nc-nd/4.0/
License	CC BY-NC-ND 4.0
Link	https://www.nature.com/articles/s41380-025-03271-y

For more information, please contact wrapteam@worc.ac.uk

PERSPECTIVE OPEN



Defining suicidality phenotypes for genetic studies: perspectives of the Psychiatric Genomics Consortium Suicide Working Group

Sarah M. C. Colbert^{1,2,3}✉, Eric T. Monson^{4,5}, Ole A. Andreassen^{6,7}, Olatunde O. Ayinde⁸, Peter B. Barr^{9,10,11,12}, Cosmin A. Bejan¹³, Zuriel Ceja^{14,15}, Hilary Coon^{4,5}, Emily DiBlasi^{4,5}, Howard J. Edenberg^{16,17}, Joel Gelernter^{18,19}, Alexander Hatoum²⁰, Anastasia Izotova^{21,22,23}, Emma C. Johnson²⁰, Erin A. Kaufman^{4,5}, Henry R. Kranzler^{24,25}, Maria Koromina^{1,2,3}, Kelli Lehto²⁶, Woojae Myung^{27,28}, John I. Nurnberger Jr.^{16,29}, Alessandro Serretti^{30,31}, Jordan W. Smoller^{32,33,34}, Murray B. Stein³⁵, Clement C. Zai^{33,36,37,38,39}, Annette Erlangsen^{40,41,42}, Marie Gaine^{43,44}, Lourdes Martorell^{45,46,47}, Reeteka Sud^{48,49}, Claudio Toma^{50,51,52}, Tim B. Bigdeli^{9,10,11,12}, Nathan A. Kimbrel^{53,54,55,56}, Douglas Ruderfer^{13,57,58}, Anna R. Docherty^{4,5,59}, J. John Mann⁶⁰ and Niamh Mullins^{1,2,3}✉, on behalf of the Psychiatric Genomics Consortium Suicide Working Group*

© The Author(s) 2025

Suicidality phenotypes, consisting of suicidal ideation (SI), suicide attempt (SA), and suicide death (SD), are all heritable but present unique challenges in genome-wide association studies (GWAS) due to their individual complexity, overlap with each other and with related self-harm phenotypes, and varying associations with psychiatric disorders. GWAS have uncovered several loci associated with suicidality phenotypes by meta-analyzing data from multiple cohorts. However, combining datasets from many research groups, where each group may use different study designs, phenotyping instruments, and definitions of suicidality phenotypes, presents challenges. Heterogeneity resulting from these differences can limit genetic discovery; harmonizing phenotype definitions to ensure consistency will greatly improve results. Here, we describe a standardized phenotyping protocol that draws on the expertise of a subgroup of clinicians, researchers, and experts from the Psychiatric Genomics Consortium Suicide Working Group to propose consensus definitions for SI, SA, and SD for genetic studies.

Molecular Psychiatry (2025) 30:6144–6154; <https://doi.org/10.1038/s41380-025-03271-y>

INTRODUCTION

Suicidality phenotypes are multidimensional, representing a range of thoughts and behaviors directed toward intentional self-injurious acts with at least partial intent to die. Suicidality phenotypes are defined within three major categories [1]: (1) suicidal ideation (SI), wherein an individual contemplates ending their own life with or without a specific plan; (2) suicide attempt (SA), wherein an individual takes action to cause harm to themselves with at least some intent to die; (3) suicide death (SD), or death caused by intentional action to take one's own life. Consistent phenotype definitions remain a challenge in suicide genetics, however, for several reasons. Suicidality phenotypes lack standardized diagnostic criteria, have considerable overlap with other self-harm phenotypes, and are often considered psychiatric symptoms rather than a distinct clinical category. Several lines of evidence support the view that suicidality phenotypes are distinct clinical categories, specifically studies demonstrating substantial unique heritability independent of psychiatric disorders [2, 3], recent recognition of suicidal behavior as a standalone diagnostic code in the DSM-5-TR [4], and the significant clinical and public health relevance of SD and SA as leading causes of preventable death and injury. Moreover,

suicidality can be directly reduced or prevented without fully resolving potentially underlying psychiatric conditions. For example, clozapine and ketamine have been associated with a reduction in suicidality that is not solely attributable to their effects on psychotic symptoms [5, 6] or depression and anxiety [7], respectively. These studies suggest that suicidality phenotypes can have partially distinct mechanisms and treatment responses, supporting their consideration as clinically meaningful phenotypes in their own right.

Genome-wide association studies (GWAS) of SI, SA, and SD have uncovered several associated genetic loci. Although the most recent GWAS of SI [8] and SD [9] were conducted in single cohorts, the formation of the Psychiatric Genomics Consortium Suicide Working Group (PGC SUI, formerly the International Suicide Genetics Consortium (ISGC)) facilitated the first organized effort to conduct GWAS meta-analyses of SA [3, 10], including over 43 000 cases from 22 diverse cohorts. GWAS meta-analyses are sensitive to the heterogeneity of the contributing cohorts. Solutions are available for handling some sources of heterogeneity, such as using inverse-variance weighted methods to meta-analyze cohorts with sample size disparities and implementing a standard analytic protocol to ensure that GWAS within

A full list of author affiliations appears at the end of the paper.

Received: 17 April 2025 Revised: 18 August 2025 Accepted: 11 September 2025

Published online: 25 September 2025

Table 1. Definitions of suicidality and self-harm phenotypes.

Phenotype (abbreviation)	Phenotype definition	Typical phenotyping sources
Suicidal ideation (SI)	Thoughts of engaging in suicide-related behavior.	Psychiatric interviews, suicide-specific rating scales, self-report questionnaires, International Classification of Diseases (ICD) codes, electronic health records
Suicide attempt (SA)	A non-fatal self-directed potentially injurious behavior with any intent to die as a result of the behavior. A suicide attempt may or may not result in injury.	
Suicide death (SD)	Death caused by self-directed injurious behavior with any intent to die as a result of the behavior.	Coroners' reports, medical examiners' reports, death registries
Non-suicidal self-injury (NSSI)	The intentional self-inflicted destruction of body tissue without suicidal intention and for purposes not socially sanctioned.	Similar to those for SI/SA (a detailed review is beyond the scope of this protocol)

Definitions are derived from Crosby et al. [1] and Cipriano et al. [18].

cohorts apply consistent data processing pipelines, statistical models, and covariates. However, heterogeneity resulting from inconsistent phenotype definitions remains a challenge in suicide genetics, as for the full range of psychiatric and substance use traits. Such heterogeneity can diminish the ability to detect genetic variations uniquely associated with a given suicidality phenotype [11, 12].

To best analyze suicidality data from varied cohorts, careful consideration of phenotyping is required to maximize comparability of these complex phenotypes across study samples to ensure robust genetic analyses. Developing a protocol for consistent suicidality phenotype definitions across cohorts in genetic studies will, therefore, be of great value. The ideal protocol will facilitate harmonization and ensure that phenotype definitions are accurate, easy to implement, and provide guidance for incorporating the varied phenotyping methods commonly used in psychiatric genetics. Definitions should also be designed to allow effective application to existing datasets and to guide the development and inclusion of new cohorts.

To address these challenges, members of PGC SUI describe here a set of guidelines for suggested best practices in defining suicidality case and control phenotypes. This protocol is implemented within PGC SUI and can be applied more broadly to research on the genetics and biology of suicidality phenotypes. Specifically, we make recommendations to derive standardized phenotypes from a variety of information sources, including clinical interviews, self-report questionnaires, suicide-specific rating scales and electronic health records (EHR). We also provide guidance on how to handle missing phenotype information, co-occurring phenotypes, and time-limited measures. Utilization of these recommendations will substantially benefit collaborative efforts by increasing participation and statistical power, improving comparability and reproducibility, and enhancing the overall quality of meta-analyses across studies.

AIM AND OBJECTIVES

PGC SUI conducts large-scale genomic analyses of suicidality phenotypes by combining data from studies worldwide. Our current priorities are to perform separate GWAS of SI, SA, and SD, dissect their shared and distinct genetic etiologies and quantify the extent to which their genetic liabilities may overlap with, or be independent from, those of co-occurring psychiatric disorders. PGC SUI designed a phenotyping protocol to enable these objectives by ensuring rigor and comparability of phenotype definitions across the cohorts in our GWAS, allowing us to study the genetics of these suicidality phenotypes both separately and together, and control for bias that may arise from the frequent co-occurrence of psychiatric disorders.

PROTOCOL DEVELOPMENT

The recommendations presented in this protocol reflect a consensus reached by PGC SUI, based on literature review, expert opinion and workgroup discussions. An initial evaluation of phenotypes used in prior GWAS and GWAS meta-analyses of suicidality was conducted by a smaller phenotyping task force, comprising clinical experts in the field along with core PGC SUI analysts. This evaluation served as the foundation for the development of the present protocol.

Specifically, we considered GWAS meta-analyses of suicide attempt conducted by ISGC [3, 10], as well as single-cohort GWAS from population-based studies like MVP [8, 13, 14] and iPSYCH [15] or cohorts specifically ascertained for suicidality, such as the Columbia University cohort [16] and the Genetic Investigation of Suicide and SA (GISS) cohort [17]. The phenotyping task force assessed the strengths and weaknesses of various definitions, ascertainment methods, and measures. We also considered how the data generated from GWAS meta-analyses of suicidality phenotypes may be used in downstream genetic analyses. We incorporated insights from literature on phenotyping in genetic research [12], with the goal of constructing phenotype definitions that are both robust and compatible with follow-up analyses. Leveraging all of this information, the phenotyping task force developed a preliminary phenotyping protocol.

This protocol was then iteratively refined in close collaboration with the broader PGC SUI working group during monthly workgroup meetings, where feedback was actively solicited and incorporated. Once a full draft of the protocol was completed, it was circulated to the working group mailing list and underwent several rounds of review and revision. All members of the working group were encouraged to provide questions, concerns, or suggestions. All members' input was weighted equally and feedback could be provided anonymously if desired. Discussions were held on monthly working group calls to resolve differences of opinion on specific recommendations. In cases where consensus could not be fully reached, solutions that accounted for multiple perspectives were adopted. The protocol was revised until all concerns from working group members were addressed. All named authors approved the final version of the protocol presented here.

PHENOTYPE DEFINITIONS

Cases: Table 1 presents the current international standard phenotype definitions for SI, SA, and SD along with non-suicidal self-injury (NSSI) [1, 18]. The present strategy of PGC SUI is to conduct GWAS focusing on each of the suicidality phenotypes, rather than combining all of them into one broad suicidality phenotype. This approach serves to maximize specificity and minimizes heterogeneity, as substantial genetic differences exist

Table 2. Control definitions for SA, SD, and SI GWAS.

GWAS phenotype (abbreviation)	Control inclusion criteria	Control exclusion criteria
Suicide attempt (SA)	Any individual reporting no history of lifetime SA. A psychiatric diagnosis or history of SI may be present. Any individual without a psychiatric diagnosis even if information on SA is not available.	Evidence of SA Evidence of SD Psychiatric diagnosis AND missing information on SA
Suicide death (SD)	Any deceased individual whose cause of death was not suicide or undetermined intent. A psychiatric diagnosis or history of SI may be present. Any living individual reporting no history of lifetime SA. A psychiatric diagnosis may be present. Any living individual without a psychiatric diagnosis even if information on SA is not available.	Evidence of SA Evidence of SD Psychiatric diagnosis AND missing information on SA Death of undetermined intent (UDI)
Suicidal ideation (SI)	Any individual reporting no history of lifetime SI. A psychiatric diagnosis may be present. Any individual without a psychiatric diagnosis even if information on SI is not available.	Evidence of SI Evidence of SA Evidence of SD Psychiatric diagnosis AND missing information on SI

between these phenotypes. For example, molecular genetics studies estimate moderate to high genetic correlations among these four phenotypes ($r_g = 0.53\text{--}0.84$), but all are significantly below 1 [19]. Similarly, twin studies estimate substantial but incomplete genetic correlations between SA and SD [20] and show differing heritability estimates among these phenotypes [21, 22]. To further maintain specificity in GWAS analyses, we propose that each suicidality case phenotype be directly assessed for the phenotype of interest using validated measures, such as clinical psychiatric interviews or self-report instruments, rather than inferred by proxy. This study design aims to increase the specificity of the GWAS of each suicidality phenotype by minimizing bias that could arise from including cohorts specifically collected for the study of a more severe suicidality phenotype. For example, the definition of SA used here specifically describes non-fatal acts, thus SD cases should not be considered as SA cases unless a previous non-fatal SA is known. Similarly, when using data from a cohort which specifically collected individuals who made a suicide attempt or died by suicide, only individuals with phenotypic information available indicating that they also meet criteria for SI should be included in an SI GWAS. Thus, all SA or SD cohorts should not automatically be meta-analyzed with SI cohorts. Although SI logically precedes SA and SD, this approach avoids constructing an overly broad ‘suicidality phenotype’ that conflates distinct clinical presentations and enriches SI samples with SA/SD cases. However, SA and SD are not exclusion criteria for SI case status. If individuals meet the criteria for SI case status outlined here, they should still be included, even if it is known that they made a suicide attempt or died by suicide. Together, these criteria ensure that each GWAS reflects the expected prevalence of more severe suicidality phenotypes in these populations. Thus, for example, an SI GWAS will proportionally reflect the full spectrum of individuals who experience SI, such that most individuals with SI do not go on to attempt or die by suicide, while some do [23, 24].

Similarly, the presence or absence of a psychiatric disorder does not impact case status, such that the sample used in a GWAS of a specific suicidality phenotype will accurately resemble the general population in relation to the prevalence of psychiatric disorders in suicidality cases. Moreover, many cohorts lack information on all three major suicidality phenotypes or complete psychiatric histories; therefore, requiring case phenotype definitions to exclude individuals with a more severe suicidality phenotype or a psychiatric disorder would likely result in a sample size that is too small to conduct a GWAS with reasonable statistical power. Finally, conducting separate and specific GWAS of each suicidality phenotype still allows subsequent genetic analysis across all

suicidality phenotypes together via meta-analysis, common factor GWAS, or similar approaches.

Controls: Controls are individuals without the case suicidality phenotype. Table 2 describes the criteria for controls in suicidality GWAS. All controls should be screened for the case phenotype and any more severe suicidality phenotypes using available information, with affected individuals being removed from the analyses. For example, controls in a GWAS of SA should be screened for SA and SD, but not SI. Individuals ascertained for having psychiatric disorders should be included within the control group, however, they should be screened for the absence of the case suicidality phenotype. Otherwise, the higher prevalence of these phenotypes amongst individuals with psychiatric disorders [25] could lead to a higher possibility of misclassification of controls. For example, individuals ascertained for psychiatric diagnoses should also be screened for SI before inclusion as controls in a GWAS of SI and should be screened for SA before inclusion as controls in a GWAS of SA and GWAS of SD. Evidence of SA is used as an additional exclusion criterion for controls in SD GWAS, since most potential controls are living. When suicidality screening is missing only for psychiatrically healthy individuals, however, the likelihood of misclassification is low, and retaining these individuals helps preserve sample size and reduce potential bias in cohorts that do not assess suicidality in all participants. When data on deceased controls and cause of death are available, individuals classified as having died by undetermined intent (UDI) should be excluded from the control group, as several studies have suggested that a proportion of UDI deaths are SDs [26–28]. When screening controls, any individual with a more severe phenotype should be excluded (e.g., any individual with evidence of SA or SD should be excluded as controls in a GWAS of SI regardless of whether there is evidence of SI). Individuals ascertained for having psychiatric disorders who are missing information on the case suicidality phenotype (e.g., they were not asked or declined to answer during their interview) should be excluded.

TYPICAL PHENOTYPING SOURCES

SI and SA data may be available from structured psychiatric interviews, and other forms of clinical instruments, scales, and questionnaires. While several suicide-specific instruments exist (e.g., the Columbia Suicide Severity Rating Scale (C-SSRS) [29]), general psychiatric instruments (e.g., the Composite International Diagnostic Interview [30], the Schedules for Clinical Assessment in Neuropsychiatry [31]) also often include items that assess suicidality phenotypes (Supplementary Tables 1–2). SI and SA phenotypes may also be derived from EHRs in the form of International Classification of Diseases (ICD) codes or clinical notes.

SD can be identified from coroners' or medical examiners' reports and death registries (such as the U.S. National Death Index or state-based registries). Here, we suggest guidelines for how these different information sources can be used to define suicidality phenotype cases and controls according to our phenotyping definitions.

SI/SA INSTRUMENT GUIDELINES

PGC SUI has developed basic guidelines for determining whether a particular item from an instrument should be used to define cases and controls for SI and SA. Most importantly, questions/items that are acceptable for use in defining SI should include the specification of thoughts of suicide or death, including terminology such as "suicidal thoughts", "better off dead", or "thoughts that life was not worth living". Questions or items that are used for identifying prior SA should include specific language regarding the attempt and, ideally, assess for a history of prior attempts at any time in the individual's life. Language for suicide attempt assessment should include phrases such as "suicide attempt", "tried to kill yourself", "intent to die", or "result in death" and avoid language that conflates SA and NSSI, such as "harm yourself" or "injure yourself." For both SI and SA questions/items, only one phenotype should be included within a question with a binary response. For example, a question that asks whether an individual has "considered or done anything to hurt yourself" with a binary "yes-no" response is unable to differentiate cases of SI, SA, and NSSI.

Time frame

Additionally, caution should be exercised with questions that assess a specified time period (e.g., the past week or past year). Although it is reasonable to include an individual as an SA case who answered "yes" to an attempt in the past year, another individual that answered negatively to such a question cannot be easily ruled out as a case, in contrast to individuals assessed with lifetime measures. When a response to a single time-limited question may be inconclusive, other factors such as psychiatric diagnostic status should be considered to determine the likelihood of a false negative. This is not to say that time-limited questions have no utility; several studies suggest that when time-limited questions are assessed repeatedly at multiple time points (as is often done in longitudinal studies), the cumulative response captures mental health conditions more accurately than a single lifetime measurement which is susceptible to recall bias [32, 33]. Therefore, the use case for time-limited questions may depend on the specific study design and the other information available. Some instruments, for example the C-SSRS, have both a time-limited and lifetime history version, and in such cases, the lifetime version should be employed at the first assessment in new cohorts ascertained for GWAS. If both time-limited and lifetime measures are available in an existing dataset, it is recommended that the most recent measure of lifetime history of suicidality be used first to determine cases and controls, and any potential missed cases can be identified using time-limited measures or earlier assessments of lifetime measures.

Inconsistencies

Individuals positive for one item but negative for another should be included as a case. Many valid inconsistencies often arise when assessments are conducted at different times or measure different periods of time. For example, a negative response at baseline but a positive response at follow-up likely indicates suicidality during the follow-up period and should result in the individual being classified as a case. Similarly, endorsement of suicidality on a lifetime assessment, but not on a time-limited (e.g., "past year") assessment, should warrant case status.

Importantly, inconsistencies across instruments assessing the same time period do not necessarily indicate measurement error. Evidence suggests that a single positive report, regardless of

modality, likely still reflects true suicidality. For instance, one study comparing ecological momentary assessments (EMA) of SI collected every day over one week with retrospective ratings from a clinician-administered interview at week's end, showed that individuals who reported SI only during EMA, but not in the interview, were no less likely to have a valid history of suicidality than those who reported consistently [34].

A related and common issue involves inconsistencies in responses to the same instrument across time points that cannot be explained by the aforementioned factors. Studies have shown that 23–43% of individuals who report a lifetime history of suicidality at baseline fail to report the same history at follow-up [35–37]. Furthermore, longitudinal studies show stable rates of lifetime suicidality across waves, despite the expectation that such rates should increase within a closed cohort over time [38]. This phenomenon is not unique to suicidality; for example, cross-sectional studies consistently report declining rates of lifetime depression and anxiety across age groups [39]. These inconsistencies likely reflect recall bias, mood congruent memory, and psychological distancing from past SI/SA, rather than initial false endorsements.

Altogether, these findings support classifying individuals as cases based on any credible endorsement of the suicidality phenotype, regardless of consistency across measures or time points. Variability in reporting across modalities or assessment windows does not undermine the validity of a positive response. However, when possible, inconsistencies should be periodically reevaluated, and the reliability and validity of assessment tools should be empirically reassessed.

Dichotomization

Several instruments, such as those which employ scales, do not use binary "yes-no" questions. Continuous traits can yield more powerful GWAS because they contain more information. However, for the purposes of contributing to a consortium or participating in a meta-analysis, it is usually best to code suicidality phenotypes as binary variables, for consistency with most other studies. Items on scales should therefore be dichotomized based on any reported evidence of a phenotype (case) and evidence of the absence of a phenotype (control). For example, the Beck Depression Inventory [40] assesses SI on a scale: 0 = "I don't have any thoughts of killing myself", 1 = "I have thoughts of killing myself, but I would not carry them out", 2 = "I would like to kill myself", 3 = "I would kill myself if I had the chance". In this item, responses 1–3 indicate varying degrees of SI, and all these scores would be defined as SI cases if the responses were dichotomized. The complete absence of SI, indicated by those who responded 0, would be used to define controls.

Minimal phenotypes

Lastly, in some scenarios, research groups may only have access to rapid screening measures that are designed to quickly identify the need for further evaluation and inform disposition decisions, resulting in a "minimal" or less specific phenotype. For example, item 9 in the popular Patient Health Questionnaire (PHQ)-9 ("Over the last 2 weeks, how often have you been bothered by thoughts that you would be better off dead, or of hurting yourself?") is a broad assessment of thoughts of self-harm that does not separate SI from thoughts of NSSI, making it less specific than more detailed evaluations [41, 42]. The PHQ-9 is widely used in healthcare and research settings, meaning that this item is often available for large cohorts such as biobanks. The use of such "minimal" phenotypes and particularly their inclusion within larger consortia efforts, should balance the trade-offs between sample size, statistical power, and potential loss of specificity. Additionally, the impact of including less-specific phenotypes can and should be assessed in many ways. The optimal benchmarking method will depend on the characteristics of the specific GWAS. One common approach is to compare SNP-heritability estimates, as

previous studies have shown that GWAS using minimal phenotypes tend to yield lower SNP-heritability estimates than those using more strictly defined phenotypes [11, 43]. However, this method is best suited for large, well-powered GWAS that yield significant SNP-heritability estimates. In the context of suicidality GWAS, benchmarking may involve comparing SNP-heritability and pairwise genetic correlations with previously validated GWAS, such as the ISGC1 GWAS of SA [3], as well as with other contributing cohorts. In cases where GWAS are underpowered due to small sample size, the variance explained (R^2) by polygenic risk scores for the suicidality phenotype in question, trained on a validated GWAS, can instead be compared across cohorts and phenotype definitions. Additionally, leave-one-out and subgroup meta-analyses, in which GWAS of minimal phenotypes are excluded, can help evaluate changes in heterogeneity statistics, offering insight based on the influence of minimal phenotypes on meta-analytic results.

Although we promote initially analyzing minimal and strict phenotype definitions separately, we encourage collecting both so that future meta-analysis efforts can evaluate how to best use different kinds of data to curate appropriate phenotype definitions for their specific purposes and goals. Given the small number of large-scale suicidality GWAS to date, our current understanding of how these “minimal” phenotypes differ genetically from more stringent definitions remains incomplete. For this reason, we do not recommend the use of rigid benchmarks at this stage. Instead, we emphasize the importance of characterizing this potential heterogeneity as a key focus of future genetic studies of suicidality. Critically, researchers should clearly and thoroughly report any benchmarking and sensitivity analyses they conduct, not only to support interpretation and discussion of their results, but also to enable other researchers to independently evaluate the reliability and robustness of the findings.

SI/SA instrument recommendations

We applied the above guidelines to a collection of instruments used in psychiatric genetic studies and/or suicide research identified by group consensus and literature review of large meta-analyses performed by various working groups of the PGC [3, 44–46]. Specific guidelines for all evaluated questionnaires, including exact questions/items and acceptable responses are provided in Supplementary Tables 1 and 2 for SA and SI, respectively. Frequently used instruments that define a minimal phenotype are also included. The instruments assessed do not represent a comprehensive evaluation of every psychiatric instrument available but rather are presented as examples of commonly used instruments that meet the best practice guidelines set in this protocol and are likely to be useful in studies that aim to construct clear and accurate definitions of SI and SA using pre-existing phenotype collections.

For new studies that aim to collect data on suicidality phenotypes, it is strongly recommended to use an instrument that provides a detailed assessment of suicidality phenotypes, has wide distribution and accessibility, offers flexible language and licensing options (preferably validated in the languages used), and adheres to broadly accepted phenotype definitions. In addition, it is recommended to use versions of instruments that assess lifetime history, whenever possible. The C-SSRS [29] meets these criteria, and it is recommended that this or a similarly constructed instrument be used in new datasets.

EHR DATA GUIDELINES

Currently, most genetic studies of suicidality phenotypes rely on clinical instruments for phenotyping; however, with the advent of large-scale, EHR-linked biobanks, it is anticipated that ICD codes and other types of EHR data (e.g., clinical notes) will become increasingly important in defining suicidality phenotypes. Several

studies have compared ICD code-based definitions with natural language processing (NLP) algorithms developed to identify suicidality phenotypes from clinical notes in EHR data. These show that standard SI/SA ICD codes alone perform poorly, and phenotyping is improved by using information from both ICD codes and clinical notes [47–51]. Efforts to develop novel ICD-9 and ICD-10 diagnostic code lists for SI and SA based on literature review and expert consensus [52, 53] still show that ICD codes underperform relative to instrument and clinical data. While ICD codes are the least accurate among phenotyping sources, abandoning their use, or EHR data altogether, would overlook the substantial value of EHR-based studies, which offer scalable, cost-efficient access to diverse real-world clinical populations. Thus, it is recommended that ICD code data be coupled with data from instruments or clinical notes when possible to enhance phenotyping, as in previous genetic studies of suicidality using EHR data [14, 49, 54]. For studies with ICD code data available, we recommend the use of the ICD code lists provided by Monson et al. [52] to define SI and SA. While NLP algorithms have shown promise in defining suicidality phenotypes in certain healthcare systems [47, 55], a standard consensus on their application has not yet been established. Thus, their use in cohorts contributing to meta-analyses should be considered on a case-by-case basis to ensure that they have been properly validated and adhere to the guidelines set above, and in particular, that the NLP algorithm can differentiate suicidality phenotypes from one another and from NSSI.

DEATH RECORDS

Suicide is conservatively attributed as a cause of death worldwide [56] so the possibility of false positive classification from death records is considered minimal. However, in some cases national death registries may serve as a more accurate source of cause of death than local or state registries, as was shown in a previous evaluation of the accuracy of firearm death determination [57]. Although some studies suggest that a substantial proportion of deaths of undetermined intent (UDIs) are SDs, and genetic epidemiology studies indicate minimal genetic differences between SD and UDI [58], these findings have yet to be confirmed in molecular genetic studies. Given our current preference for conservative phenotype definitions which allow us to better examine genetic similarities and differences among specific suicidality phenotypes, we do not consider UDIs suitable for inclusion in SD GWAS.

CO-OCCURRING PSYCHIATRIC DISORDERS

Psychiatric disorders are major risk factors for suicidality phenotypes and are often comorbid with them. The prevalence of psychiatric disorders is estimated to range between 43–52% among SI cases, 55–66% among SA cases [25], and 60–98% among SD cases [59, 60]. The high comorbidity of psychiatric disorders with suicidality phenotypes can bias GWAS towards detecting associations with psychiatric disorders if not appropriately controlled. Because the lifetime prevalence of psychiatric disorders in the general population is ~30% [61], retaining individuals with psychiatric diagnoses in the control group may increase statistical power to detect associations specific to the suicidality phenotype (Fig. 1A). Conversely, removing all individuals with psychiatric disorders from the control group, while retaining individuals with psychiatric disorders in the case group (Fig. 1C), would increase the likelihood of identifying associations with psychiatric phenotypes generally rather than the suicidality phenotype [12], distort estimates of variance explained [62], and bias genetic correlations [63]. PGC SUI recommends screening for the absence of the case suicidality phenotype and any more severe suicidality phenotype, and retaining individuals with




Fig. 1 Schematic of comparison between SA cases versus potential control groups with varying prevalence of psychiatric disorders. A–C The left panels represent SA cases, and the right panels represent the control group. Amongst SA cases, the prevalence of psychiatric disorders is 0.9. **A** The population control group displays psychiatric disorders at a prevalence of 0.3 and SA at a prevalence of 0.02. **B** The SA-screened control group displays psychiatric disorders at a prevalence of 0.3. **C** The non-psychiatric control group assumes a prevalence of 0 for both psychiatric disorders and SA.

psychiatric diagnoses in the control group (Fig. 1B). The use of such controls, as opposed to completely unscreened controls or only psychiatrically healthy controls, maximizes statistical power without introducing substantial bias to the GWAS [12]. While psychiatrically healthy controls are often used in psychiatric genetic studies, we advise against removing controls with psychiatric disorders in suicidality studies. Such exclusion risks producing GWAS results that would likely measure differences not just between individuals with and without suicidality, but also differences between those with and without psychiatric disorders more broadly [63]. In turn, this can inflate genetic correlations or generate spurious associations between a target phenotype and any secondary phenotype screened out of the control group, as has been seen in studies on other psychiatric phenotypes [63, 64].

LIMITATIONS

Some potential limitations of our phenotyping protocol should be noted. As described in the Phenotype Definitions section, our case phenotype definitions do not exclude individuals with a more severe suicidality phenotype, a strategy used in some previous GWAS [8]. Although this stricter exclusion approach may enhance specificity, it is constrained by the availability of detailed phenotypic data for all suicidality phenotypes. Most datasets lack comprehensive information on all suicidality phenotypes, and imposing strict exclusions would substantially reduce sample sizes to levels that make GWAS infeasible. Our protocol was designed to balance the ideal phenotype definitions with those that are practical given existing data, and to provide the flexibility to investigate the distinct and shared genetic etiology of suicidality phenotypes. Additionally, although PGC SUI is an international working group, the nuances in terminology and phenotype definitions focused on in this protocol may differ or not be relevant in specific languages, cultures, and contexts. When this is the case, we suggest that the broad ideas of this protocol be considered while relying primarily on the expert opinion of clinicians and scientists familiar with the specific context. Finally, our perspectives are based on current knowledge and best practices in the field. As our understanding of the components of suicidality and their phenotypic definitions continues to evolve, these recommendations may need to be refined. Therefore, we encourage consortia to prioritize the collection of comprehensive phenotypic data at the individual level whenever possible, to allow for centralized phenotype reconstruction as needed.

CONCLUSION

Here we provide the perspectives of PGC SUI on defining SI, SA, and SD phenotypes for genetic studies and comprehensive phenotyping protocols. Recognizing the many complexities in these phenotypes and the sources from which they are derived, we present proposed standard definitions and guidelines to address these challenges and ensure consistency. By harmonizing phenotypes across cohorts, this protocol aims to reduce heterogeneity, increase power in meta-analyses, and improve the comparability and reproducibility of genetic studies. Use of this protocol by PGC SUI and the greater suicide research community is expected to increase collaborative research efforts and advance understanding of the genetic underpinnings of suicidality.

REFERENCES

- Crosby A, Ortega LV, Melanson C. Self-directed violence surveillance; uniform definitions and recommended data elements. National Center for Injury Prevention and Control (U.S.). Division of Violence Prevention; 2011.
- Fu Q, Heath AC, Bucholz KK, Nelson EC, Glowinski AL, Goldberg J, et al. A twin study of genetic and environmental influences on suicidality in men. *Psychol Med*. 2002;32:11–24.
- Mullins N, Kang J, Campos AI, Coleman JRI, Edwards AC, Galfalvy H, et al. Dissecting the shared genetic architecture of suicide attempt, psychiatric disorders, and known risk factors. *Biol Psychiatry*. 2022;91:313–27.
- American Psychiatric Association, issuing body. *Diagnostic and statistical manual of mental disorders: DSM-5-TR*. American Psychiatric Association Publishing; 2022. <https://doi.org/10.1001/archpsyc.60.1.82>.
- Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry*. 2003;60:82–91.
- Masdrakis VG, Baldwin DS. Prevention of suicide by clozapine in mental disorders: systematic review. *Eur Neuropsychopharmacol*. 2023;69:4–23.
- Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. *J Psychiatr Res*. 2014;58:161–6.
- Ashley-Koch AE, Kimbrel NA, Qin XJ, Lindquist JH, Garrett ME, Dennis MF, et al. Genome-wide association study identifies four pan-ancestry loci for suicidal ideation in the Million Veteran Program. *PLoS Genet*. 2023;19:e1010623.
- Docherty AR, Shabalin AA, DiBlasi E, Monson E, Mullins N, Adkins DE, et al. Genome-wide association study of suicide death and polygenic prediction of clinical antecedents. *Am J Psychiatry*. 2020;177:917–27.
- Docherty AR, Mullins N, Ashley-Koch AE, Qin X, Coleman JRI, Shabalin A, et al. GWAS meta-analysis of suicide attempt: identification of 12 genome-wide significant loci and implication of genetic risks for specific health factors. *Am J Psychiatry*. 2023;180:723–38.
- Cai N, Revez JA, Adams MJ, Andlauer TFM, Breen G, Byrne EM, et al. Minimal phenotyping yields genome-wide association signals of low specificity for major depression. *Nat Genet*. 2020;52:437–47.

12. Cai N, Verhulst B, Andreassen OA, Buitelaar J, Edenberg HJ, Hettema JM, et al. Assessment and ascertainment in psychiatric molecular genetics: challenges and opportunities for cross-disorder research. *Mol Psychiatry*. 2025;30:1627–38.
13. Kimbrel NA, Ashley-Koch AE, Qin XJ, Lindquist JH, Garrett ME, Dennis MF, et al. Identification of novel, replicable genetic risk loci for suicidal thoughts and behaviors among US military veterans. *JAMA Psychiatry*. 2023;80:135–45.
14. Kimbrel NA, Ashley-Koch AE, Qin XJ, Lindquist JH, Garrett ME, Dennis MF, et al. A genome-wide association study of suicide attempts in the million veterans program identifies evidence of pan-ancestry and ancestry-specific risk loci. *Mol Psychiatry*. 2022;27:2264–72.
15. Erlangsen A, Appadurai V, Wang Y, Turecki G, Mors O, Werge T, et al. Genetics of suicide attempts in individuals with and without mental disorders: a population-based genome-wide association study. *Mol Psychiatry*. 2020;25:2410–21.
16. Galfalvy H, Haghighi F, Hodgkinson C, Goldman D, Oquendo MA, Burke A, et al. A genome-wide association study of suicidal behavior. *Am J Med Genet B Neuropsychiatr Genet*. 2015;168:557–63.
17. Sokolowski M, Wasserman J, Wasserman D. Polygenic associations of neurodevelopmental genes in suicide attempt. *Mol Psychiatry*. 2016;21:1381–90.
18. Cipriano A, Cella S, Cotrufo P. Nonsuicidal self-injury: a systematic review. *Front Psychol*. 2017;8:1946.
19. Colbert SMC, Mullins N, Chan G, Meyers JL, Schulman J, Kuperman S, et al. Polygenic contributions to suicidal thoughts and behaviors in a sample ascertained for alcohol use disorders. *Complex Psychiatry*. 2023;9:11–23.
20. Edwards AC, Ohlsson H, Mościcki E, Crump C, Sundquist J, Lichtenstein P, et al. On the genetic and environmental relationship between suicide attempt and death by suicide. *Am J Psychiatry*. 2021;178:1060–9.
21. Voracek M, Loibl LM. Genetics of suicide: a systematic review of twin studies. *Wien Klin Wochenschr*. 2007;119:463–75.
22. Brent DA, Mann JJ. Family genetic studies, suicide, and suicidal behavior. *Am J Med Genet C Semin Med Genet*. 2005;133C:13–24.
23. Beck AT, Steer RA, Kovacs M, Garrison B. Hopelessness and eventual suicide: a 10-year Prospective study of patients hospitalized with suicidal ideation. *Am J Psychiatry*. 1985;142:559–63.
24. Nock MK, Borges G, Bromet EJ, Alonso J, Angermeyer M, Beautrais A, et al. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. *Br J Psychiatry*. 2008;192:98–105.
25. Nock MK, Hwang I, Sampson N, Kessler RC, Angermeyer M, Beautrais A, et al. Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys. *PLoS Med*. 2009;6:e1000123.
26. Fernandez JM, Jayawardhana J. Are suicides underreported? The impact of coroners versus medical examiners on suicide reporting. *Health Serv Res*. 2025;60:e14381.
27. Snowdon J, Choi NG. Undercounting of suicides: where suicide data lie hidden. *Glob Public Health*. 2020;15:1894–901.
28. Pritchard C, Iqbal W, Dray R. Undetermined and accidental mortality rates as possible sources of underreported suicides: population-based study comparing Islamic countries and traditionally religious Western countries. *BJPsych Open*. 2020;6:e56.
29. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry*. 2011;168:1266–77.
30. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. *Arch Gen Psychiatry*. 1988;45:1069–77.
31. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. *Arch Gen Psychiatry*. 1990;47:589–93.
32. Haeny AM, Littlefield AK, Sher KJ. Repeated diagnoses of lifetime alcohol use disorders in a prospective study: insights into the extent and nature of the reliability and validity problem. *Alcohol Clin Exp Res*. 2014;38:489–500.
33. Moffitt TE, Caspi A, Taylor A, Kokaua J, Milne BJ, Polanczyk G, et al. How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. *Psychol Med*. 2010;40:899–909.
34. Gratch I, Choo T-H, Galfalvy H, Keilp JG, Itzhaky L, Mann JJ, et al. Detecting suicidal thoughts: the power of ecological momentary assessment. *Depress Anxiety*. 2021;38:8–16.
35. Klimes-Dougan B, Safer MA, Ronsaville D, Tinsley R, Harris SJ. The value of forgetting suicidal thoughts and behavior. *Suicide Life Threat Behav*. 2007;37:431–8.
36. Goldney RD, Winefield AH, Winefield HR, Saebel J. The benefit of forgetting suicidal ideation. *Suicide Life Threat Behav*. 2009;39:33–7.
37. Eikelenboom M, Smit JH, Beekman ATF, Kerkhof AJFM, Penninx BWJH. Reporting suicide attempts: consistency and its determinants in a large mental health study: reporting suicide attempts. *Int J Methods Psychiatr Res*. 2014;23:257–66.
38. Hart SR, Musci RJ, Ialongo N, Ballard ED, Wilcox HC. Demographic and clinical characteristics of consistent and inconsistent longitudinal reporters of lifetime suicide attempts in adolescence through young adulthood: research article: consistent reporting of A suicide attempt. *Depress Anxiety*. 2013;30:997–1004.
39. Streiner DL, Patten SB, Anthony JC, Cairney J. Has lifetime prevalence reached the end of its life? An examination of the concept: lifetime prevalence. *Int J Methods Psychiatr Res*. 2009;18:221–8.
40. Beck A, Steer R, Carbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. *Clinical Psychology Review*. 1988;8:77–100.
41. Na PJ, Yaramala SR, Kim JA, Kim H, Goes FS, Zandi PP, et al. The PHQ-9 Item 9 based screening for suicide risk: a validation study of the Patient Health Questionnaire (PHQ)-9 Item 9 with the Columbia Suicide Severity Rating Scale (C-SSRS). *J Affect Disord*. 2018;232:34–40.
42. Chung TH, Hanley K, Le Y-C, Merchant A, Nascimento F, De Figueiredo JM, et al. A validation study of PHQ-9 suicide item with the Columbia Suicide Severity Rating Scale in outpatients with mood disorders at National Network of Depression Centers. *J Affect Disord*. 2023;320:590–4.
43. O'Connell KS, Koromina M, van der Veen T, Boltz T, David FS, Yang JMK, et al. Genomics yields biological and phenotypic insights into bipolar disorder. *Nature*. 2025;639:968–75.
44. Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat Neurosci*. 2019;22:343–52.
45. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat Genet*. 2021;53:817–29.
46. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*. 2022;604:502–8.
47. Bejan CA, Ripberger M, Wilimitis D, Ahmed R, Kang J, Robinson K, et al. Improving ascertainment of suicidal ideation and suicide attempt with natural language processing. *Sci Rep*. 2022;12:15146.
48. Callahan ST, Fuchs DC, Shelton RC, Balmer LS, Dudley JA, Gideon PS, et al. Identifying suicidal behavior among adolescents using administrative claims data: IDENTIFYING SUICIDAL BEHAVIOR USING CLAIMS DATA. *Pharmacopeidemiol Drug Saf*. 2013;22:769–75.
49. Colbert SMC, Lepow L, Fennessy B, Iwata N, Ikeda M, Saito T, et al. Distinguishing clinical and genetic risk factors for suicidal ideation and behavior in a diverse hospital population. *Transl Psychiatry*. 2025;15:63.
50. Fernandes AC, Dutta R, Velupillai S, Sanyal J, Stewart R, Chandran D. Identifying suicide ideation and suicidal attempts in a psychiatric clinical research database using Natural Language Processing. *Sci Rep*. 2018;8:7426.
51. Walkup JT, Townsend L, Crystal S, Olsson M. A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data: METHODS FOR IDENTIFYING SUICIDE USING CLAIMS DATA. *Pharmacopeidemiol Drug Saf*. 2012;21(Suppl 1):174–82.
52. Monson ET, Colbert SMC, Barr PB, Bejan CA, Andreassen OA, Ayinde OO, et al. Defining and Assessing International Classification of Disease Suicidality Phenotypes for Genetic Studies. *medRxiv*:2024.07.27.24311110. 2025. <https://doi.org/10.1101/2024.07.27.24311110>.
53. Barak-Corren Y, Castro VM, Javitt S, Hoffnagle AG, Dai Y, Perlis RH, et al. Predicting suicidal behavior from longitudinal electronic health records. *Am J Psychiatry*. 2017;174:154–62.
54. Coon H, Shabalin AA, Monson ET, DiBlasi E, Han S, Baird LM, et al. Different genetic liabilities to neuropsychiatric conditions in suicides with no prior suicidality. *medRxiv*:2025.05.02.25326877. 2025.
55. Cusick M, Velupillai S, Downs J, Campion TR Jr, Sholle ET, Dutta R, et al. Portability of natural language processing methods to detect suicidality from clinical text in US and UK electronic health records. *J Affect Disord Rep*. 2022;10:100430.
56. Tøllefsen IM, Hem E, Ekeberg Ø. The reliability of suicide statistics: a systematic review. *BMC Psychiatry*. 2012;12:9.
57. Barber C, Hemenway D. Too many or too few unintentional firearm deaths in official U.S. mortality data? *Accid Anal Prev*. 2011;43:724–31.
58. Edwards AC, Ohlsson H, Mościcki EK, Sundquist J, Crump C, Kendler KS, et al. Genetic differences between suicide deaths and deaths of undetermined intent. *Suicide Life Threat Behav*. 2023;53:100–9.
59. Bachmann S. Epidemiology of suicide and the psychiatric perspective. *Int J Environ Res Public Health*. 2018;15:1425.
60. Cavanagh JTO, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. *Psychol Med*. 2003;33:395–405.

61. Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. *Int J Epidemiol*. 2014;43:476–93.
62. Preacher KJ, Rucker DD, MacCallum RC, Nicewander WA. Use of the extreme groups approach: a critical reexamination and new recommendations. *Psychol Methods*. 2005;10:178–92.
63. Kendler KS, Chatzinakos C, Bacanu S-A. The impact on estimations of genetic correlations by the use of super-normal, unscreened, and family-history screened controls in genome wide case-control studies. *Genet Epidemiol*. 2020;44:283–9.
64. Schwartz S, Susser E. The use of well controls: an unhealthy practice in psychiatric research. *Psychol Med*. 2011;41:1127–31.

ACKNOWLEDGEMENTS

This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. 1842169 (PI Colbert) and the National Institute of Mental Health R01MH132733 (PI Mullins). We thank and acknowledge all members of the Psychiatric Genomics Consortium Suicide Working group.

AUTHOR CONTRIBUTIONS

SMCC, ETM, DR, ARD, JJM, and NM designed the protocol and phenotype definitions. SMCC drafted the manuscript with assistance from ETM. SMCC conducted the review of phenotyping sources and instruments. JJM and NM supervised the work and provided overall direction. All authors (SMCC, ETM, OAA, OOA, PBB, CAB, ZC, HC, ED, HJE, JG, AH, AI, ECJ, EAK, HRK, MK, KL, WM, JIN, AS, JWS, MBS, CCZ, AE, MG, LM, RS, CT, TBB, NAK, DR, ARD, JJM, NM) revised the manuscript and approved the final version.

COMPETING INTERESTS

Ole Andreassen: Consultant to Cortechs.ai and Precision-Health.ai, and received speaker's honorarium from Lundbeck, Sunovion, Janssen and Otsuka. Murray Stein: MBS has in the past 3 years received consulting income from Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, Boehringer Ingelheim, Delix Therapeutics, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, Karuna Therapeutics, Lykos Therapeutics, NeuroTrauma Sciences, Otsuka US, PureTech Health, Sage Therapeutics, Seaport Therapeutics, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). He is on the scientific advisory board of the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. John Mann: Dr. Mann receives royalties for commercial use of the C-SSRS from the Research Foundation of Mental Hygiene and from Columbia University for the Columbia Pathways App. Jordan Smoller: Dr. Smoller is a member of the Scientific Advisory Board of Sensorium

Therapeutics (with options), and has received grant support from Biogen, Inc. He is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. Henry Kranzler: Dr. Kranzler is a member of advisory boards for Altimmune and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Imbrium, Indivior, Kinovio, Lilly, Otsuka, and Pear; and an inventor on U.S. provisional patent "Multi-ancestry Genome-wide Association Meta-analysis of Buprenorphine Treatment Response". All other listed authors declare no conflicts of interest.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41380-025-03271-y>.

Correspondence and requests for materials should be addressed to Sarah M. C. Colbert or Niamh Mullins.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2025

¹Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ²Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ³Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁴Department of Psychiatry, University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, UT, USA. ⁵Huntsman Mental Health Institute, Salt Lake City, UT, USA. ⁶Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. ⁷NORMENT Centre, University of Oslo, Oslo, Norway. ⁸Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria. ⁹Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. ¹⁰VA New York Harbor Healthcare System, New York, NY, USA. ¹¹Institute for Genomics in Health, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. ¹²Department of Epidemiology and Biostatistics, School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY, USA. ¹³Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA. ¹⁴Mental Health and Neuroscience Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. ¹⁵School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. ¹⁶Department of Medical & Molecular Genetics, Indiana University, Bloomington, IN, USA. ¹⁷Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Bloomington, IN, USA. ¹⁸Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. ¹⁹Department of Psychiatry, VA CT Healthcare System, West Haven, CT, USA. ²⁰Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. ²¹Research Department, Lovisenberg Diaconal Hospital, Oslo, Norway. ²²PsychGen Centre for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo, Norway. ²³Department of Psychology, University of Oslo, Oslo, Norway. ²⁴Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. ²⁵Mental Illness Research, Education and Clinical Center, Crescenz VA Medical Center, Philadelphia, PA, USA. ²⁶Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia. ²⁷Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, South Korea. ²⁸Department of Psychiatry, Seoul National University College of Medicine, Seongnam, South Korea. ²⁹Department of Psychiatry, Indiana University School of Medicine, Bloomington, IN, USA. ³⁰Department of Medicine and Surgery, Kore University of Enna, Enna, Italy. ³¹Oasi Research Institute-IRCCS, Troina, Italy. ³²Center for Precision Psychiatry, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. ³³Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, USA. ³⁴Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, MA, USA. ³⁵Department of Psychiatry and School of Public Health, University of California San Diego, La Jolla, CA, USA. ³⁶Department of Psychiatry, University of Toronto, Toronto, ON, Canada. ³⁷Institute of Medical Science, University of Toronto, Toronto, ON, Canada. ³⁸Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. ³⁹Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. ⁴⁰Center of Mental Health Research, Australian National University, Canberra, ACT, Australia. ⁴¹Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ⁴²Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark. ⁴³The Department of Pharmaceutical Sciences and Experimental Therapeutics (PSET), College of Pharmacy, University of Iowa, Iowa City, IA, USA. ⁴⁴Iowa Neuroscience Institute, University of Iowa, Iowa City, IA, USA. ⁴⁵Research department, Hospital Universitari Institut Pere Mata, IISPV-CERCA, Reus, Spain. ⁴⁶Psychiatry Unit, Universitat Rovira i Virgili, Reus, Spain. ⁴⁷Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III,

Madrid, Spain. ⁴⁸Center for Brain and Mind, Department of Psychiatry, NIMHANS, Bangalore, India. ⁴⁹Molecular Genetics Laboratory, Department of Psychiatry, NIMHANS, Bangalore, India. ⁵⁰Centre for Molecular Biology Severo Ochoa (CBMSO), The Spanish National Research Council (CSIC) & Autonomous University of Madrid, Madrid, Spain. ⁵¹Neuroscience Research Australia, Sydney, NSW, Australia. ⁵²School of Clinical Medicine, Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, NSW, Australia. ⁵³Durham VA Health Care System, Durham, NC, USA. ⁵⁴VA Health Services Research and Development Center of Innovation to Accelerate Discovery and Practice Transformation, Durham, NC, USA. ⁵⁵VISN 6 Mid-Atlantic Mental Illness Research, Education, and Clinical Center, Durham, NC, USA. ⁵⁶Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA. ⁵⁷Vanderbilt Genetics Institute, Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. ⁵⁸Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. ⁵⁹Clinical and Translational Science Institute & the Center for Genomic Medicine, University of Utah, Salt Lake City, UT, USA. ⁶⁰Departments of Psychiatry and Radiology, Columbia University, New York, NY, USA. *A list of authors and their affiliations appears at the end of the paper. [✉]email: sarah.colbert@icahn.mssm.edu; niamh.mullins@mssm.edu

THE PSYCHIATRIC GENOMICS CONSORTIUM SUICIDE WORKING GROUP

Sarah MC Colbert^{1,2,3}, Eric T. Monson^{4,5}, Ole A. Andreassen^{6,7}, Olatunde Ayinde⁸, Peter B. Barr^{9,10,11,12}, Cosmin A. Bejan¹³, Zuriel Ceja^{14,15}, Hilary Coon^{16,17}, Emily DiBlasi^{18,19}, Howard J. Edenberg²⁰, Joel Gelernter^{21,22,23}, Alexander S. Hatoum²⁴, Anastasia Izotova^{25,26,27}, Emma C. Johnson²⁸, Erin A. Kaufman²⁹, Henry R. Kranzler^{30,31}, Maria Koromina^{32,33,34}, Kelli Lehto³⁵, Woojae Myung^{36,37,38,39}, John I. Nurnberger Jr.^{40,41,42}, Alessandro Serretti^{43,44}, Jordan W. Smoller^{45,46,47}, Murray B. Stein^{48,49}, Clement C. Zai^{50,51,52}, Annette Erlangsen^{53,54,55,56}, Marie Gaine^{57,58}, Lourdes Martorell^{59,60}, Reeteka Sud^{61,62}, Claudio Toma^{63,64,65}, Tim B. Bigdeli^{66,67,68}, Nathan A. Kimbrel^{69,70,71,72}, Douglas M. Ruderfer^{73,74,75}, Anna R. Docherty^{76,77,78}, J. John Mann^{79,80}, Niamh Mullins^{81,82,83}, Mark Adams⁸⁴, Rolf Adolfsson^{85,86,87}, Ingrid Agartz^{88,89,90}, Esben Agerbo^{91,92,93}, Tracy M. Air⁹⁴, Martin Alda^{95,96}, Lars Alfredsson^{97,98}, Adebayo Anjorin⁹⁹, Vivek Appadurai^{100,101,102}, Maria Soler Artigas^{103,104,105}, Allison E. Ashley-Koch¹⁰⁶, Swapnil Awasthi¹⁰⁷, M. Helena Azevedo^{108,109,110,111}, Enrique Baca Garcia^{112,113,114}, Amanda Bakian¹¹⁵, Nicholas Bass¹¹⁶, Claiton HD Bau^{117,118}, Bernhard T. Baune^{119,120}, Jean C. Beckham^{121,122,123}, Frank Bellivier^{124,125,126}, Andrew W. Bergen^{127,128}, Klaus Berger¹²⁹, Wade H. Berrettini¹³⁰, Joanna M. Biernacka^{131,132,133}, Tim B. Bigdeli^{134,135,136}, Elisabeth B. Binder^{137,138,139}, Michael Boehnke^{140,141,142}, Martin Bohus¹⁴³, Marco P. Boks¹⁴⁴, Anders D. Borglum^{145,146,147,148}, Rosa Bosch^{149,150,151,152}, David L. Braff^{153,154,155}, Harry Brandt^{156,157,158}, Gerome Breen^{159,160,161}, Richard Bryant¹⁶², Monika Budde¹⁶³, Cynthia M. Bulik^{164,165,166}, Enda M. Byrne^{167,168,169}, Wiepke Cahn^{170,171,172}, Adrian I. Campos^{173,174,175}, Miguel Casas^{176,177,178,179}, Enrique Castelao¹⁸⁰, Jorge A. Cervilla^{181,182,183}, Xiao Chang^{184,185,186}, Boris Chaumette^{187,188,189}, Hsi-Chung Chen^{190,191,192}, Wei J. Chen^{193,194,195}, Erik D. Christensen^{196,197,198}, Sven Cichon^{199,200,201,202}, Jonathan R. I. Coleman^{203,204,205}, Aiden Corvin^{206,207,208}, Nicholas Craddock^{209,210,211}, David Craig^{212,213,214}, Steven Crawford^{215,216,217}, Scott Crow^{218,219,220}, Franziska Degenhardt^{221,222,223}, Ditte Demontis^{224,225,226}, Michelle Dennis^{227,228,229}, Srdjan Djurovic^{230,231,232}, Philibert Duriez^{233,234,235}, Alexis Edwards^{236,237,238}, Tõnu Esko^{239,240,241}, Giuseppe Fanelli^{242,243,244}, Ayman H. Fanous^{245,246,247}, Fernando Fernández-Aranda^{248,249,250}, Manfred M. Fichter^{251,252,253}, Jerome C. Foote^{254,255,256}, Andreas J. Forstner^{257,258,259}, Gabriel R. Fries²⁶⁰, Mark Frye^{261,262,263}, Janice M. Fullerton^{264,265,266}, Hanga Galfalvy^{267,268,269}, Steven Gallinger^{270,271,272}, Michael Gandal^{273,274,275}, Melanie Garrett^{276,277,278}, Justine M. Gatt^{279,280,281}, Pablo V. Gejman^{282,283,284}, Ina Giegling^{285,286,287}, Stephen J. Glatt^{288,289,290}, Philip Gorwood^{291,292,293}, Hans J. Grabe^{294,295,296}, Melissa J. Green^{297,298,299}, Eugenio H. Grevet^{300,301,302}, Maria Grigoriou-Serbanescu^{303,304,305}, Yiran Guo^{306,307,308}, Blanca Gutierrez^{309,310,311}, Alfonso Gutierrez-Zotes^{312,313,314}, Jose Guzman-Parra^{315,316,317}, Jonathan D. Hafferty^{318,319,320}, Lauren Hair^{321,322,323}, Hakon Hakonarson^{324,325,326}, Katherine A. Halmi^{327,328,329}, Steven P. Hamilton^{330,331,332}, Marian L. Hamshere^{333,334,335}, Annette M. Hartmann^{336,337,338}, Philip Harvey^{339,340,341}, Elizabeth R. Hauser^{342,343,344}, Michael A. Hauser^{345,346,347}, Joanna Hauser^{348,349,350}, Stefanie Heilmann-Heimbach^{351,352,353}, Akitoyo Hishimoto^{354,355,356}, Per Hoffmann^{357,358,359}, David M. Hougaard^{360,361,362}, Jennifer Huffman^{363,364,365}, Hai-Gwo Hwu^{366,367,368}, Marcus Ising^{369,370,371}, Daniel Jacobson^{372,373,374}, Sonia Jain^{375,376,377}, Stéphane Jamain^{378,379,380}, Min Ji^{381,382,383}, Susana Jiménez-Murcia^{384,385,386}, Craig Johnson^{387,388,389}, Ian Jones^{390,391,392}, Lisa A. Jones^{393,394,395}, Lina Jonsson^{396,397,398}, René S. Kahn^{399,400,401}, JooEun Kang^{402,403,404}, Allan S. Kaplan^{405,406,407}, Walter H. Kaye^{408,409,410}, Pamela K. Keel^{411,412,413}, John R. Kelsoe^{414,415,416}, Kenneth S. Kendler^{417,418,419}, James L. Kennedy^{420,421,422}, Ronald C. Kessler^{423,424,425}, Minsoo Kim^{426,427,428}, Stefan Kloiber^{429,430,431}, Kelly L. Klump^{432,433,434}, Karestan C. Koenen^{435,436,437}, Manolis Kogevinas^{438,439,440}, Bettina Konte^{441,442,443}, Marie-Odile Krebs^{444,445,446}, Po-Hsiu Kuo^{447,448,449}, Mikael Landén^{450,451,452}, Séverine Lannoy^{453,454,455}, Jacob Lawrence^{456,457,458}, Marion Leboyer^{459,460,461}, Phil H. Lee^{462,463,464}, Daniel F. Levey^{465,466,467}, Douglas F. Levinson^{468,469,470}, Cathryn M. Lewis^{471,472,473}, Dong Li^{474,475,476}, Qingqin S. Li^{477,478,479}, Shih-Cheng Liao^{480,481,482}, Calwing Liao^{483,484,485}, Klaus Lieb^{486,487,488}, Lisa Lilienfeld^{489,490,491}, Jennifer H. Lindquist^{492,493,494}, Jolanta Lissowska^{495,496,497}, Chih-Min Liu^{498,499,500}, Adriana Lori^{501,502,503}, Susanne Lucae^{504,505,506}, Ravi Madduri^{507,508,509}, Pierre J. Magistretti^{510,511,512}, Christian R. Marshall^{513,514,515}, Nicholas G. Martin^{516,517,518}, Fermin Mayoral^{519,520,521}, Susan L. McElroy^{522,523,524}, Patrick McGrath^{525,526,527}, Peter McGuffin^{528,529,530}, Andrew M. McIntosh^{531,532,533}, Benjamin McMahon^{534,535,536}, Andrew McQuillin^{537,538,539}, Sarah E. Medland^{540,541,542}, Divya Mehta^{543,544,545}, Ingrid Melle^{546,547,548}, Yuri Milaneschi^{549,550,551}, James E. Mitchell^{552,553,554}, Philip B. Mitchell^{555,556,557}, Esther Molina^{558,559,560}, Gunnar Morken^{561,562,563}, Ole Mors^{564,565,566}, Preben Bo Mortensen^{567,568,569}, Bertram Müller-Myhsok^{570,571,572}, Gerard Muntané^{573,574,575}, Balasz Murnyak^{576,577,578}, Richard M. Myers^{579,580,581}, Caroline Nievergelt^{582,583,584}, Vishwajit Nimgaonkar^{585,586,587}, Merete Nordentoft^{588,589,590}, Markus M. Nöthen^{591,592,593}, Michael C. O'Donovan^{594,595,596}, Satoshi Okazaki^{597,598,599}, Catherine M. Olsen^{600,601,602}, Roel A. Ophoff^{603,604,605}, David W. Oslin^{606,607,608}, Ikuo Otsuka^{609,610,611}, Michael J. Owen^{612,613,614}, Sergi Papiol^{615,616,617}, Carlos Pato^{618,619,620}, Michele T. Pato^{621,622,623}, Brenda WJH Penninx^{624,625,626}, Jonathan Pimm^{627,628,629}, Dalila Pinto^{630,631,632}, Giorgio Pistis^{633,634,635}, Renato Polimanti^{636,637,638}, David Porteous^{639,640,641}, James B. Potash^{642,643,644}, Robert A. Power^{645,646,647}, Abigail Powers^{648,649,650}, Martin Preisig^{651,652,653}, Xuejun Qin^{654,655,656}, Digby Quedstedt^{657,658,659}, Josep Antoni Ramos-Quiroga^{660,661,662}, Nicolas Ramoz^{663,664,665}, Andreas Reif^{666,667,668}, Miguel E. Rentería^{669,670,671}, Marta Ribasés^{672,673,674}, Vanesa Richarte^{675,676,677}, Marcella Rietschel^{678,679,680}, Stephan Ripke^{681,682,683}, Margarita Rivera^{684,685,686}, Andrea Roberts^{687,688,689}, Gloria Roberts^{690,691,692}, Stefan Roepke^{693,694,695}, Guy A. Rouleau^{696,697,698}, Diego L. Rovaris^{699,700,701}, Vsevolod Rozanov^{702,703,704}, Dan Rujescu^{705,706,707}, Vanessa Sánchez-Gistau^{708,709,710}, Cristina Sánchez-Mora^{711,712,713}, Alan R. Sanders^{714,715,716}, Chelsea Sawyers^{717,718,719}, Stephen W. Scherer^{720,721,722}, Christian Schmahl^{723,724,725}, Peter R. Schofield^{726,727,728}, Thomas G. Schulze^{729,730,731}, Laura J. Scott^{732,733,734}, Andrey Shabalín^{735,736,737}, Jianxin Shi^{738,739,740}, Stanley I. Shyn^{741,742,743}, Lea Sirignano^{744,745,746}, Pamela Sklar^{747,748,749}, Olav B. Smeland^{750,751,752}, Daniel J. Smith^{753,754,755}, Marcus Sokolowski^{756,757,758}, Edmund J. S. Sonuga-Barke^{759,760,761}, Gianfranco Spalletta^{762,763,764}, Eli A. Stahl^{765,766,767}, Anna Starnawska^{768,769,770}, Mallory Stephenson^{771,772,773}, John S. Strauss^{774,775,776}, Fabian Streit^{777,778,779}, Michael Strober^{780,781,782}, Mei-Hsin Su^{783,784,785}, Beata Świątkowska^{786,787,788}, Laura M. Thornton^{789,790,791}, Jodie Trafton^{792,793,794}, Janet Treasure^{795,796,797}, Maciej Trzaskowski^{798,799,800}, Ming T. Tsuang^{801,802,803}, Gustavo Turecki^{804,805,806}, Robert J. Ursano^{807,808,809}, Sandra Van der Auwera^{810,811,812}, Laura Vilar-Ribó^{813,814,815}, Elisabet Vilella^{816,817,818}, John B. Vincent^{819,820,821}, Henry Völzke^{822,823,824}, Consuelo Walss-Bass^{825,826,827}, James TR Walters^{828,829,830}, Erin B. Ware^{831,832,833}

Danuta Wasserman²⁸⁴, Hunna J. Watson^{122,304,305}, Cynthia Shannon Weickert^{51,175,306}, Thomas W. Weickert^{51,175,306}, Myrna M. Weissman^{307,308}, Frank Wendt¹⁸, Thomas Werge^{68,75,309,310}, David C. Whiteman²⁵⁰, Leanne M. Williams³¹¹, Virginia Willour³¹², Stephanie H. Witt²⁸⁹, D. Blake Woodside^{36,37,313,314}, Naomi R. Wray^{124,236}, Zeynep Yilmaz^{67,122,315} and Lea Zillich²⁸⁹

⁶¹Division of Psychiatry, University of Edinburgh, Edinburgh, UK. ⁶²Department of Clinical Sciences, Psychiatry, Umeå University Medical Faculty, Umeå, Sweden. ⁶³Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway. ⁶⁴Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden. ⁶⁵NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. ⁶⁶Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark. ⁶⁷National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark. ⁶⁸The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark. ⁶⁹Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia. ⁷⁰Department of Psychiatry, Dalhousie University, Halifax, NS, Canada. ⁷¹National Institute of Mental Health, Klecany, CZ, Czechia. ⁷²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. ⁷³Inst of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ⁷⁴Psychiatry, Berkshire Healthcare NHS Foundation Trust, Bracknell, UK. ⁷⁵Institute of Biological Psychiatry, Copenhagen Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark. ⁷⁶The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Copenhagen, Denmark. ⁷⁷Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain. ⁷⁸Department of Genetics, Microbiology & Statistics, University of Barcelona, Barcelona, Spain. ⁷⁹Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. ⁸⁰Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA. ⁸¹Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany. ⁸²Department of Psychiatry, University of Coimbra, Coimbra, Portugal. ⁸³Department of Psychiatry, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain. ⁸⁴Department of Psychiatry, Autonomous University of Madrid, Madrid, Spain. ⁸⁵Division of Psychiatry, University College London, London, UK. ⁸⁶Laboratory of Developmental Psychiatry, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. ⁸⁷Department of Genetics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. ⁸⁸Department of Psychiatry, University of Münster, Germany, Münster, NRW, Germany. ⁸⁹Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia. ⁹⁰The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia. ⁹¹VISN 6 Mid-Atlantic Mental Illness Research, Education, and Clinical Center, Durham Veterans Affairs Health Care System, Durham, NC, USA. ⁹²Department of Psychiatry and Addiction Medicine, Assistance Publique - Hôpitaux de Paris, Paris, France. ⁹³Paris Bipolar and TRD Expert Centres, FondaMental Foundation, Paris, France. ⁹⁴UMR-S1144 Team 1 : Biomarkers of relapse and therapeutic response in addiction and mood disorders, INSERM, Paris, France. ⁹⁵Psychiatry, Université Paris Cité, Paris, France. ⁹⁶BioRealm, LLC, Walnut, CA, USA. ⁹⁷Oregon Research Institute, Eugene, OR, USA. ⁹⁸Institute of Epidemiology and Social Medicine, University of Münster, Münster, Nordrhein-Westfalen, Germany. ⁹⁹Department of Psychiatry, Center for Neurobiology and Behavior, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. ¹⁰⁰Health Sciences Research, Mayo Clinic, Rochester, MN, USA. ¹⁰¹Department of Psychiatry and Behavioral Sciences, State University of New York Downstate Medical Center, New York, NY, USA. ¹⁰²Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA. ¹⁰³Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. ¹⁰⁴Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany. ¹⁰⁵Center for Statistical Genetics and Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA. ¹⁰⁶Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. ¹⁰⁷Psychiatry, UMC Utrecht Brain Center, Utrecht, Netherlands. ¹⁰⁸Centre for Genomics and Personalized Medicine, CGPM, Aarhus University, Aarhus, Denmark. ¹⁰⁹Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark. ¹¹⁰Department of Biomedicine, Aarhus University, Aarhus, Denmark. ¹¹¹The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus University, Aarhus, Denmark. ¹¹²Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. ¹¹³Department of Psychiatry, University of California San Diego, La Jolla, CA, USA. ¹¹⁴ERCPATHlight, Baltimore, MD, USA. ¹¹⁵University of Maryland St. Joseph Medical Center, Baltimore, MD, USA. ¹¹⁶National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, King's College London, London, UK. ¹¹⁷Social Genetic and Developmental Psychiatry Centre, King's College London, London, UK. ¹¹⁸School of Psychology, University of New South Wales, Sydney, NSW, Australia. ¹¹⁹Institute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU Munich, Munich, Germany. ¹²⁰Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ¹²¹Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ¹²²Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ¹²³Child Health Research Centre, The University of Queensland, Brisbane, QLD, Australia. ¹²⁴Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia. ¹²⁵Department of Psychiatry, UMC Utrecht Hersencentrum Rudolf Magnus, Utrecht, Netherlands. ¹²⁶Mental Health and Neuroscience Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. ¹²⁷Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland. ¹²⁸Mental Health Unit, Department of Psychiatry, Faculty of Medicine, Granada University Hospital Complex, University of Granada, Granada, Spain. ¹²⁹Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. ¹³⁰Institut de Psychiatrie, CNRS GDR 3557 Paris, France. ¹³¹Department of Evaluation, Prevention and Therapeutic innovation, GHU Paris Psychiatrie et Neurosciences, Paris, France. ¹³²Team Pathophysiology of psychiatric diseases, Université de Paris, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Paris, France. ¹³³Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan. ¹³⁴Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan. ¹³⁵Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. ¹³⁶Utah Office of the Medical Examiner, Utah Department of Health and Human Services, Taylorsville, UT, USA. ¹³⁷Department of Pathology, University of Utah, Salt Lake City, UT, USA. ¹³⁸Institute of Neuroscience and Medicine (INM-1), Research Centre Jülich, Jülich, Germany. ¹³⁹Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. ¹⁴⁰Department of Biomedicine, University of Basel, Basel, Switzerland. ¹⁴¹Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany. ¹⁴²Neuropsychiatric Genetics Research Group, Dept of Psychiatry and Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. ¹⁴³Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. ¹⁴⁴Department of Translational Genomics, University of Southern California, Pasadena, CA, USA. ¹⁴⁵Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA. ¹⁴⁶Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA. ¹⁴⁷Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway. ¹⁴⁸Hôpital Sainte Anne, GHU Paris Psychiatrie et Neurosciences, Paris, France. ¹⁴⁹Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Université Paris Cité, Paris, France. ¹⁵⁰Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, US. ¹⁵¹Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, US. ¹⁵²Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia. ¹⁵³Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. ¹⁵⁴Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. ¹⁵⁵Department of Psychiatry, University Hospital Bellvitge-IDIBELL and CIBEROBN, Barcelona, Spain. ¹⁵⁶Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University (LMU), Munich, Germany. ¹⁵⁷Schön Klinik Rosenneck affiliated with the Medical Faculty of the University of Munich (LMU), Munich, Germany. ¹⁵⁸Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. ¹⁵⁹Centre for Human Genetics, University of Marburg, Marburg, Germany. ¹⁶⁰Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA. ¹⁶¹Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA. ¹⁶²School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia. ¹⁶³Department of Biostatistics, Columbia University, New York, NY, USA. ¹⁶⁴Department of Psychiatry, Columbia University, New York, NY, USA. ¹⁶⁵Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. ¹⁶⁶Department of Psychiatry and Biobehavioral Science, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. ¹⁶⁷Duke University Medical Center, Durham, NC, USA. ¹⁶⁸Department of Psychiatry and Behavioral Sciences, NorthShore University HealthSystem, Evanston, IL, USA. ¹⁶⁹Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA. ¹⁷⁰Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria. ¹⁷¹Department of Psychiatry, University of Munich, Munich, Germany. ¹⁷²Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. ¹⁷³Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany. ¹⁷⁴Partner Site Rostock/Greifswald, German Centre for Neurodegenerative Diseases (DZNE), Greifswald, Mecklenburg-Vorpommern, Germany. ¹⁷⁵School of Psychiatry, University of New South Wales, Sydney, NSW, Australia. ¹⁷⁶ADHD Outpatient Program, Adult Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. ¹⁷⁷Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. ¹⁷⁸Biometric Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania. ¹⁷⁹Department of Psychiatry, Faculty of Medicine and Biomedical Research Centre (CIBM), University of Granada, Granada, Spain. ¹⁸⁰Mental Health Department, University Regional Hospital. Biomedicine Institute (IBIMA), Málaga, Spain. ¹⁸¹Durham Veterans Affairs Health Care System, Durham, NC, USA. ¹⁸²The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ¹⁸³Department of Psychiatry, Weill Cornell Medical College, New York, NY, USA. ¹⁸⁴Psychiatry, Kaiser Permanente Northern California, San Francisco, CA, USA. ¹⁸⁵Miami VA Health Care System, Miami, FL, USA.

¹⁸⁶Cooperative Studies Program Epidemiology Center, Durham Veterans Affairs Health Care System, Durham, NC, USA. ¹⁸⁷Psychiatric Genetics, Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland. ¹⁸⁸Department of Psychiatry, Yokohama City University Graduate School of Medicine, Yokohama, Japan. ¹⁸⁹Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark. ¹⁹⁰Boston VA Health Care System, Boston, MA, USA. ¹⁹¹Department of Psychiatry, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan. ¹⁹²Max Planck Institute of Psychiatry, Munich, Germany. ¹⁹³Oak Ridge National Laboratory, Oak Ridge, TN, USA. ¹⁹⁴Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. ¹⁹⁵IMRB, Translational Neuropsychiatry, Fondation FondaMental, Univ Paris-Est-Créteil, INSERM, Créteil, France. ¹⁹⁶Eating Recovery Center, Denver, CO, USA. ¹⁹⁷Department of Psychological Medicine, University of Worcester, Worcester, UK. ¹⁹⁸Department of Psychiatry and Neuroscience, University of Gothenburg, Gothenburg, Sweden. ¹⁹⁹Psychiatry, UMC Utrecht Brain Center Rudolf Magnus, Utrecht, Netherlands. ²⁰⁰Division of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. ²⁰¹Centre for Addiction and Mental Health, Toronto, ON, Canada. ²⁰²Department of Psychiatry, University of California San Diego, San Diego, CA, USA. ²⁰³Department of Psychology, Florida State University, Tallahassee, FL, USA. ²⁰⁴Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA. ²⁰⁵Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. ²⁰⁶Department of Psychology, Michigan State University, Lansing, MI, USA. ²⁰⁷Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA. ²⁰⁸Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. ²⁰⁹Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. ²¹⁰Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden. ²¹¹Psychiatry, North East London NHS Foundation Trust, Ilford, UK. ²¹²IMRB, Translational Neuropsychiatry, DMU IMPACT, FHU ADAPT, Fondation FondaMental, Univ Paris Est Créteil, INSERM, AP-HP, Créteil, France. ²¹³INSERM, Paris, France. ²¹⁴Faculté de Médecine, Université Paris Est, Créteil, France. ²¹⁵Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. ²¹⁶Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. ²¹⁷Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA. ²¹⁸Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. ²¹⁹Psychiatry & Behavioral Sciences, Stanford University, Stanford, CA, USA. ²²⁰Department of Medical & Molecular Genetics, King's College London, London, UK. ²²¹Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA. ²²²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ²²³Analytical and Translational Genetics Unit, Massachusetts General Hospital, Cambridge, MA, USA. ²²⁴Department of Psychiatry and Psychotherapy, University Medical Center, Mainz, Germany. ²²⁵Department of Clinical Psychology, The Chicago School of Professional Psychology, Washington DC, Washington, DC, USA. ²²⁶VA Health Services Research and Development Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA. ²²⁷Cancer Epidemiology and Prevention, M. Skłodowska-Curie Cancer Center and Institute of Oncology, Warsaw, Poland. ²²⁸University of Chicago Consortium for Advanced Science and Engineering, Argonne National Laboratory, Chicago, IL, USA. ²²⁹BESE Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia. ²³⁰Department of Psychiatry, University of Lausanne-University Hospital of Lausanne (UNIL-CHUV), Lausanne, Switzerland. ²³¹Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada. ²³²Research Institute, Lindner Center of HOPE, Mason, OH, USA. ²³³Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA. ²³⁴Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA. ²³⁵School of Psychology and Counseling, Queensland University of Technology, Brisbane, QLD, Australia. ²³⁶Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia. ²³⁷Division of Mental Health and Addiction, University of Oslo, Institute of Clinical Medicine, Oslo, Norway. ²³⁸Department of Psychiatry, Amsterdam UMC, Vrije Universiteit and GGZ inGeest, Amsterdam, Netherlands. ²³⁹Department of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA. ²⁴⁰Department of Nursing, Faculty of Health Sciences and Biomedical Research Centre (CIBM), University of Granada, Granada, Spain. ²⁴¹Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology - NTNU, Trondheim, Norway. ²⁴²Psychiatry, St Olavs University Hospital, Trondheim, Norway. ²⁴³Psychosis Research Unit, Aarhus University Hospital, Risskov, Aarhus, Denmark. ²⁴⁴Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. ²⁴⁵University of Liverpool, Liverpool, UK. ²⁴⁶HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA. ²⁴⁷Psychiatry and Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA. ²⁴⁸Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark. ²⁴⁹Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan. ²⁵⁰Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. ²⁵¹Psychiatry, Erasmus University Medical Center, Rotterdam, Netherlands. ²⁵²VISN 4 Mental Illness Research, Education, and Clinical Center, Corporal Michael J. Crescenzo VA Medical Center, Philadelphia, PA, USA. ²⁵³Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ²⁵⁴Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany. ²⁵⁵Department Clinical Translation, Max Planck Institute of Psychiatry, Munich, Germany. ²⁵⁶RWJMS, NJMS, UBHC, Rutgers University, Piscataway, NJ, USA. ²⁵⁷RWJMS, NJMS, Rutgers University, Piscataway, NJ, USA. ²⁵⁸Department of Psychiatry and Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands. ²⁵⁹Institute for Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. ²⁶⁰Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ²⁶¹Genetics, BioMarin Pharmaceuticals, London, UK. ²⁶²St Edmund Hall, University of Oxford, Oxford, UK. ²⁶³Department of Psychiatry, University of Oxford, Oxford, UK. ²⁶⁴Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt, Germany. ²⁶⁵Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, Germany. ²⁶⁶Department of Biochemistry and Molecular Biology II and Institute of Neurosciences, Biomedical Research Centre (CIBM), University of Granada, Granada, Spain. ²⁶⁷Department of Environmental Health, Harvard TH Chan School of Public Health, Boston, MA, USA. ²⁶⁸Department of Psychiatry, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Campus Benjamin Franklin, Berlin, Germany. ²⁶⁹Department of Neurology and Neurosurgery, McGill University, Faculty of Medicine, Montreal, QC, Canada. ²⁷⁰Montreal Neurological Institute and Hospital, Montreal, QC, Canada. ²⁷¹Department of Physiology and Biophysics, Instituto de Ciencias Biomédicas Universidade de São Paulo, São Paulo, SP, Brazil. ²⁷²Department of Psychology, Saint-Petersburg State University, Saint-Petersburg, Russian Federation. ²⁷³Department of Borderline Disorders and Psychotherapy, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint-Petersburg, Russian Federation. ²⁷⁴Department of Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, ON, Canada. ²⁷⁵McLaughlin Center, University of Toronto, Toronto, ON, Canada. ²⁷⁶Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney, NSW, Australia. ²⁷⁷Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, US. ²⁷⁸Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA. ²⁷⁹Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany. ²⁸⁰Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. ²⁸¹Behavioral Health Services, Kaiser Permanente Washington, Seattle, WA, USA. ²⁸²Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ²⁸³Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. ²⁸⁴National Centre for Suicide Research and Prevention of Mental Ill-Health (NASP), LIME, Karolinska Institutet, Stockholm, Sweden. ²⁸⁵Institute of Psychology, Psychiatry & Neuroscience, King's College London, London, UK. ²⁸⁶Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA. ²⁸⁷Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy. ²⁸⁸Analytical Genetics and Data Science, Regeneron Genetics Center, Tarrytown, NY, USA. ²⁸⁹Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. ²⁹⁰David Geffen School of Medicine, University of California Los Angeles, Los Angeles, LA, USA. ²⁹¹Department of Psychiatry and Biobehavioral Science, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, LA, USA. ²⁹²Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland. ²⁹³VA Program Evaluation and Resource Center, VA Palo Alto Health Care System, Palo Alto, CA, USA. ²⁹⁴Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, King's College London, London, UK. ²⁹⁵National Institute for Health Research Biomedical Research Centre, King's College London and South London and Maudsley National Health Service Foundation Trust, London, UK. ²⁹⁶Center for Behavioral Genomics, Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA. ²⁹⁷Department of Psychiatry, McGill University, Montreal, QC, Canada. ²⁹⁸Department of Psychiatry, Uniformed Services of the Health Sciences, Bethesda, MD, USA. ²⁹⁹Molecular Brain Science, Centre for Addiction and Mental Health, Toronto, ON, Canada. ³⁰⁰Institute for Community Medicine, University Medicine Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany. ³⁰¹Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, USA. ³⁰²Population Studies Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. ³⁰³Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. ³⁰⁴School of Psychology, Curtin University, Perth, WA, Australia. ³⁰⁵Division of Paediatrics, The University of Western Australia, Perth, WA, Australia. ³⁰⁶Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA. ³⁰⁷Columbia University College of Physicians and Surgeons, New York, NY, USA. ³⁰⁸Division of Translational Epidemiology, New York State Psychiatric Institute, New York, NY, USA. ³⁰⁹Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. ³¹⁰Lundbeck Foundation GeoGenetics Centre, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark. ³¹¹Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA. ³¹²Department of Psychiatry, University of Iowa, Iowa City, IA, USA. ³¹³Centre for Mental Health, University Health Network, Toronto, ON, Canada. ³¹⁴Program for Eating Disorders, University Health Network, Toronto, ON, Canada. ³¹⁵Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.